1. Lee HL, Bae SH, Jang B, Hwang S, Yang H, Nam HC, et al. Reactivation of hepatitis C virus and its clinical outcomes in patients treated with systemic chemotherapy or immunosuppressive therapy. Gut Liver. 2017; 11:870–7.
Article
2. Torres HA, Hosry J, Mahale P, Economides MP, Jiang Y, Lok AS. Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study. Hepatology. 2018; 67:36–47.
Article
3. Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol. 2013; 19:7867–73.
Article
4. Kwon HM, Shin K, Moon JY, Lee SS, Chung WT, Lee J, et al. Transaminase changes in Korean rheumatoid arthritis patients with chronic hepatitis C after biologic therapy. J Rheum Dis. 2018; 25:108–15.
Article
5. Pawlotsky JM. Chronic viral and autoimmune hepatitis. Goldman L, Schafer AI, editors. Goldman-Cecil medicine. 25th ed.New York: Elsevier;2016. p. 1000–6.
Article
6. Maylin S, Laouénan C, Martinot-Peignoux M, Panhard X, Lapalus M, Nicolas-Chanoine MH, et al. Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy. J Clin Virol. 2012; 53:43–7.
Article
7. Ooka K, Lim JK. Treatment of hepatitis C in patients undergoing immunosuppressive drug therapy. J Clin Transl Hepatol. 2016; 4:206–27.
8. Economides MP, Mahale P, Kyvernitakis A, Turturro F, Kantarjian H, Naing A, et al. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Aliment Pharmacol Ther. 2016; 44:1235–41.
Article
9. Zein NN. Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005; 42:315–22.
Article